rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

Ongelooflijk deze: DARA

151 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 »» | Laatste | Omlaag ↓
  1. p/o 28 augustus 2010 17:45

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    Voor wat het waard is:

    The SRGV deal wil price Monday night and trade on Tuesday. The deal is done and has been but there were some paperwork issues that needed to get cleaned up and from my understanding they are done with them. But guys, lets be serious, dont count on this deal getting done as the cure all for DARA. This SRGV deal has been known about since January and was probably priced in to the company already. Nothing has changed at the company. Prior to the reverse split the stock was being day traded by a bunch of gangsters and one of the ways to get rid of them was to reverse the stock. A dumb idea i know but what you have now are day trader stragglers with odd lots who are tired of waiting for something to happen. Aside from DARA being able to monetize SRGV the company still needs to produce results. Having said that they are presenting at the pain conference on Sept 1 and hopefully whatever data they provide will get people excited about the company again. In the meantime the stock blows as does the market.
  4. p/o 2 september 2010 21:03

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    2.75 +0.43 +18.53

    hoeveel zal hier aan het eind van de dag van overblijven??
  5. [verwijderd] 8 september 2010 16:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    DARA Announces Analytical Results in Efficacy and Dose Response of KRN5500 in Patients with Chemotherapy Induced Peripheral Neuropathy and Advanced Cancer
    13th World Congress on Pain, Montreal, Canada


    ShareretweetEmailPrintCompanies:DARA BioSciences, Inc Related Quotes
    Symbol Price Change
    DARA 2.32 +0.10

    DARA BioSciences, Inc. On Wednesday September 8, 2010, 10:00 am

    RALEIGH, N.C., Sept. 8, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences (Nasdaq:DARA - News) announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.

    The study was designed to evaluate the safety and efficacy of KRN5500 for treatment of neuropathic pain in patients with cancer, and primary endpoint results from the study have previously been released.

    Prevalence of Chemotherapy-induced Peripheral Neuropathy (CIPN) is reported to be as high as 38% in patients who receive multi-agent chemotherapy. Presently, there is no approved treatment for this indication; thus, exploratory analyses of a subset of study patients with CIPN (17 of 19 total) provides clinically meaningful information regarding KRN5500 as potential treatment for CIPN.

    Wilcoxon Rank Sum test was used to compare treatment differences in median changes from baseline in pain scores recorded by patients in a daily diary.

    KRN5500 significantly reduced neuropathic pain when compared to placebo (27% vs. 0%; p = 0.03) when looking at best response to treatment regardless of dose or timing. For the best response within 7 days of last treatment given, the difference was in favor of KRN5500, but was not statistically significant (16% vs. 0%; p=0.19). In addition, regression analysis of the best response for each patient over doses showed a significant linear decrease in pain intensity with increase in dose (slope = -18.2; p = 0.009).

    Results of these analyses indicate that KRN5500 was effective in reducing pain in patients with CIPN; and a dose-response relationship was established, with higher doses resulting in greater reductions in pain. In addition, KRN5500 was generally well tolerated with adverse reactions limited to nausea and vomiting.

    Earlier this year the National Cancer Institute and DARA entered into a clinical trial collaboration to further study KRN5500 for the treatment of CIPN.
  6. p/o 10 september 2010 10:09

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    Ze zijn bij DARA de zeeeer lage beurskoers ook moe

    KRN5500 Data Looks Strong

    On September 8, 2010, DARA BioSciences (NasdaqCM: DARA) presented positive study results from its phase II dose escalation study with KRN5500 at the 13th World Congress on Pain. The multicenter, placebo-controlled phase II study was designed to evaluate the safety and efficacy of KRN5500 for treatment of neuropathic pain in patients with cancer.

    Management used the Wilcoxon Rank Sum test to compare treatment differences in median changes from baseline in pain scores recorded by patients in a daily diary. Results show:

    * KRN5500 significantly reduced neuropathic pain when compared to placebo (27% vs. 0%; p = 0.03) when looking at best response to treatment regardless of dose or timing.
    * For the best response within 7 days of last treatment given, the difference was in favor of KRN5500, but was not statistically significant (16% vs. 0%; p=0.19).
    * In addition, regression analysis of the best response for each patient over doses showed a significant linear decrease in pain intensity with increase in dose (slope = -18.2; p = 0.009).

    These results indicate that KRN5500 was effective in reducing pain in patients with chemotherapy induced peripheral neuropathy (CIPN) in a dose-response relationship. The data show that higher doses of KRN5500 result in greater reductions in pain over time. In addition, KRN5500 was generally well tolerated with adverse reactions limited to nausea and vomiting.

    In April 2010, DARA Bio announced that it has entered into a clinical trial agreement on KRN5500 with the Division of Cancer Prevention (DCP), National Cancer Institute (NCI), National Institutes of Health (NIH), for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo at costs plus expenses.

    We note that DARA will supply (at cost) DCP-NCI with a new improved nano-emulsion formulation of KRN5500. The new formulation has been proved equivalent and is that is lyophilized to provide for easier dosing administration. The NCI will utilize its established national network of investigators (Community Clinical Oncology Program -- CCOP) to conduct the planed phase IIb study. We expect this program will begin in the second half of 2010.

    With DCP-NCI handling the costs and expenses for the planned phase II program in CIPN, DARA is now free to explore additional indications with KRN5500, including post-herpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), and HIV-associated distal neuropathy (HIV-DSP). Management plans to use the proceeds from the SurgiVision IPO to fund the phase IIa proof-of-concept data on the next wave of indications for KRN5500.

    We expect that these phase IIa programs will be similar to the phase IIa conducted in CIPN. That program was a 14-week (multi-center/double-blind) placebo-controlled dose escalation study that randomized 19 terminally ill cancer patients to receive treatment with either KRN5500 (n=12) or placebo (n=7) in doses ranging from 0.6 to 2.2 mg/m2.

    DB959 Moving Forward

    In March 2009, the U.S. FDA cleared DARA’s investigational new drug (IND) application allowing management to commence phase I clinical testing of DB959 in humans. The phase I study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility. The main objectives are to determine the safety (maximum tolerated dose) and pharmacokinetics (pk) of single ascending oral doses of DB959. The company expects to report the results of the study during the second half of 2010 -- our best guess is September / October 2010.

    DARA will also conduct a food-effect study in a sub-set of the 75 patients looking at the effects of taking dosing DB959 at mealtimes. We expect the trial to cost DARA roughly $1 million. The next step would be a phase Ib multiple ascending dose program to begin in late 2010 or early 2011. After that, a larger-scale phase II study in which DARA plans to study DB959 as both monotherapy and in combination with other standard glucose lowering agents such as metformin, dipeptidyl-peptidase IV (DPP-4) inhibitors and sulphonylureas (SU).

    DARA is also conducting a 2-year carcinogenicity program on DB959, as well as a 29-day toxicology study so that all the preclinical data can be analyzed and in hand by the time the company is ready to seek a development or out-license partner on DB959 in 2012. Management plans to use the proceeds from the SurgiVision IPO to fund these programs.

    Stock Undervalued

    DARA is currently trading with a market capitalization of only $7 million. We believe the company can secure a licensing and development partner on KRN5500 in the area of $25 million, with backend milestones totaling $250 to $300 million. We base this on historical deals for phase II molecules in neuropathic pain. We base this on three previous deals between large pharmaceutical companies and small biotech firms with similar stage molecules for neuropathic pain. These deals are outlined in our report.

    Additionally, we believe that the company is progressing toward proof-of-concept data with phase I candidate, DB959, for type 2 diabetes. It’s our belief that DARA should be able to fetch $25 to $40 million as an upfront payment for KRN5500 sometime in the next several quarters.
  8. [verwijderd] 14 september 2010 21:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    bertje007 schreef:

    www.wsw.com/webcast/rrshq18/dara/

    We zouden deze week nog enkele spectaculaire persberichten mogen verwachten.
    Volgens mij ben jij nog de enige die dit aandeel volgt. Zit je er zwaar in, ik heb tijd geleden mijn verlies gepakt. Mocht die verder zakken naar de €1,80 durf ik wel longs op te pakken.
  12. p/o 16 september 2010 15:46

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    Met 10.000 stuks knallen we 24.55 %, we hebben dus maar weinig aandelen nodig om fors hoger te gaan.
    Wanneer hij zoals beloofd (eerst zien dus)vandaag of morgen met schitterende vooruitzichten kan komen en vooruitbetalingen van 25 miljoen en meer dan staat dit aandeel zo boven de 4.
    En dan droom ik nog niet zoals bepaald in Amerika ;-) ..BIG NEWS IN TWO WEEKS..= 700% UP

    De ceo kocht de afgelopen weken bij voor zo’n kleine 25.000
    Insider Transactions Reported - Last Two Years
    Date Insider Shares Type Transaction Value*
    Sep 2, 2010 FRANCO RICHARD AOfficer
    5,000 Direct Purchase at $2.64 per share. $13,200
    Aug 31, 2010 FRANCO RICHARD AOfficer
    5,000 Direct Purchase at $2.29 per share. $11,450

  13. p/o 16 september 2010 17:50

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    We stijgen meer dan 42% en het blijft hier zo stil.

    Hij beloofde deze week een persbericht, dus waarschijnlijk morgen fantastisch nieuws en dan hopelijk terug boven de 4. VOLUME is vandaag ook gigantisch
  14. p/o 16 september 2010 22:11

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    mooi slot:
    3.20 Up 0.96 (+42.86%) 3:59PM EDT

    benieuwd met wat ze morgen zullen uitpakken.
  15. [verwijderd] 16 september 2010 22:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    domus muris schreef:

    Ik zit er ook nog in. Ben er niet blij mee, maar soms veranderd dat. Ik hou ze nog even.
    Soms veranderd het. Ik hou ze nog even....
    (Ben inmiddels iets blijer:)
  17. p/o 17 september 2010 16:04

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    Even gepiekt op 3.74, maar nu blijkbaar snel terug de andere kant uit. ;-(
  18. [verwijderd] 20 september 2010 12:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Boer zoekt geld schreef:

    Dames en heren,

    Ik volg jullie al sinds half juli met veel interesse.

    De eerste verhalen gingen steeds over een "on-ontdekte" diamant voor de prijs van een liter melk; te mooi om waar te zijn.

    Nu de prijs gehalveerd is, zegt zelfs deze boer met kiespijn volmondig JA.

    Een mooi vrouwtje zoeken die samen met mij de koeien wil melken lukt me niet, maar een paar dollars verdienen zal toch wel lukken.

    Ik heb vanavond voor 2 dollars en 20 centjes per stuk 2000 keer DARA gekocht in het beloofde land. Ik geloof in een betere toekomst, net als mijn voorouders, die naar Noord Amerika zijn getrokken in de grote depressie.

    Afijn, ik hou het kort, moet vroeg op.

    Geldboer
    De boer zag, keek hoe het gewas opkwam en was tevreden met het resultaat. Het gras groeit het hardst als je met vakantie bent. Ben net terug van mijn kwekerijen in Portugal (lekker weer trouwens), waat het ook goed boeren was, het fruit hangt er mooi bij.

    Mooi om te zien dat de dollars met zo'n 50% renderen.

    Boer laat het gewas nog even verder groeien, alvorens te oogsten.

    De groenten,

    Geldboer
  19. p/o 20 september 2010 15:48

    • p/o

      Lid sinds: 17 jun 2001

      Laatste bezoek: 05 mrt 2025

    • Aanbevelingen

      Ontvangen: 233

      Gegeven: 53

    •    Aantal posts: 5.300

    Aan de koers te zien geen slechte zet

    DARA Biosciences, Inc.
    (NasdaqCM: DARA)
    Last Trade: 3.78

    Change: Up 0.43 (+12.84%)
    Prev Close: 3.35
    Open: 3.78

    Er zijn maar 2 analisten die het aandeel volgen, maar zelfs met de helft van het laagste koersdoel zou ik al dik tevreden zijn:
    Median Target: 14.00
    High Target: 16.00
    Low Target: 12.00
151 Posts
Pagina: «« 1 ... 3 4 5 6 7 8 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.097
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.863
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.772
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.764
Aedifica 3 923
Aegon 3.258 322.961
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.896
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.220
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.019
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.503
AMG 971 134.010
AMS 3 73
Amsterdam Commodities 305 6.735
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.848
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.333
Aroundtown SA 1 220
Arrowhead Research 5 9.747
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.444
ASML 1.766 108.744
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.690
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.412